RESUMEN
Studies are lacking on long-term effects among retinoblastoma patients in low- and middle-income countries. Therefore, we examined cause-specific mortality in a retrospective cohort of retinoblastoma patients treated at Antonio Candido de Camargo Cancer Center (ACCCC), São Paulo, Brazil from 1986 to 2003 and followed up through December 31, 2018. Vital status and cause of death were ascertained from medical records and multiple national databases. We estimated overall and cause-specific survival using the Kaplan-Meier survival method, and estimated standardized mortality ratios (SMRs) and absolute excess risk (AER) of death. This cohort study included 465 retinoblastoma patients (42% hereditary, 58% nonhereditary), with most (77%) patients diagnosed at advanced stages (IV or V). Over an 11-year average follow-up, 80 deaths occurred: 70% due to retinoblastoma, 22% due to subsequent malignant neoplasms (SMNs) and 5% to non-cancer causes. The overall 5-year survival rate was 88% consistent across hereditary and nonhereditary patients (p = .67). Hereditary retinoblastoma patients faced an 86-fold higher risk of SMN-related death compared to the general population (N = 16, SMR = 86.1, 95% CI 52.7-140.5), corresponding to 42.4 excess deaths per 10,000 person-years. This risk remained consistent for those treated with radiotherapy and chemotherapy (N = 10, SMR = 90.3, 95% CI 48.6-167.8) and chemotherapy alone (N = 6, SMR = 80.0, 95% CI 35.9-177.9). Nonhereditary patients had only two SMN-related deaths (SMR = 7.2, 95% CI 1.8-28.7). There was no excess risk of non-cancer-related deaths in either retinoblastoma form. Findings from this cohort with a high proportion of advanced-stage patients and extensive chemotherapy use may help guide policy and healthcare planning, emphasizing the need to enhance early diagnosis and treatment access in less developed countries.
Asunto(s)
Retinoblastoma , Humanos , Retinoblastoma/mortalidad , Retinoblastoma/terapia , Brasil/epidemiología , Masculino , Femenino , Estudios Retrospectivos , Preescolar , Lactante , Niño , Neoplasias de la Retina/mortalidad , Neoplasias de la Retina/terapia , Causas de Muerte , Tasa de Supervivencia , Adolescente , Adulto , Adulto Joven , Estimación de Kaplan-MeierRESUMEN
BACKGROUND AND PURPOSE: To predict treatment-related cardiovascular disease (CVD) and second cancer 30-year absolute mortality risks (AMR30) for patients with mediastinal Hodgkin lymphoma in a large multicentre radiation oncology network in Ireland. MATERIAL AND METHODS: This study includes consecutive patients treated for mediastinal lymphoma using chemotherapy and involved site radiotherapy (RT) 2016-2019. Radiation doses to heart, left ventricle, cardiac valves, lungs, oesophagus, carotid arteries and female breasts were calculated. Individual CVD and second cancer AMR30 were predicted using Irish background population rates and dose-response relationships. RESULTS: Forty-four patients with Hodgkin lymphoma were identified, 23 females, median age 28 years. Ninety-eight percent received anthracycline, 80% received 4-6 cycles ABVD. Volumetric modulated arc therapy (VMAT) ± deep inspiration breath hold (DIBH) was delivered, median total prescribed dose 30 Gy. Average mean heart dose 9.8 Gy (range 0.2-23.8 Gy). Excess treatment-related mean AMR30 from CVD was 2.18% (0.79, 0.90, 0.01, 0.13 and 0.35% for coronary disease, heart failure, valvular disease, stroke and other cardiac diseases), 1.07% due to chemotherapy and a further 1.11% from RT. Excess mean AMR30 for second cancers following RT were: lung cancer 2.20%, breast cancer in females 0.34%, and oesophageal cancer 0.28%. CONCLUSION: For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Asunto(s)
Enfermedades Cardiovasculares , Enfermedad de Hodgkin , Linfoma , Neoplasias del Mediastino , Neoplasias Primarias Secundarias , Radioterapia de Intensidad Modulada , Humanos , Femenino , Adulto , Radioterapia de Intensidad Modulada/efectos adversos , Enfermedad de Hodgkin/tratamiento farmacológico , Enfermedad de Hodgkin/radioterapia , Neoplasias Primarias Secundarias/epidemiología , Neoplasias Primarias Secundarias/etiología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Contencion de la Respiración , Dosificación Radioterapéutica , Órganos en Riesgo/efectos de la radiación , Bleomicina , Dacarbazina , Doxorrubicina , Vinblastina , Corazón/efectos de la radiación , Neoplasias del Mediastino/etiología , Neoplasias del Mediastino/radioterapia , Enfermedades Cardiovasculares/etiología , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
PURPOSE: An accurate assessment of out-of-field dose is necessary to estimate the risk of second cancer after radiotherapy and the damage to the organs at risk surrounding the planning target volume. Although treatment planning systems (TPSs) calculate dose distributions outside the treatment field, little is known about the accuracy of these calculations. The aim of this work is to thoroughly compare the out-of-field dose distributions given by two algorithms implemented in the Monaco TPS, with measurements and full Monte Carlo simulations. METHODS: Out-of-field dose distributions predicted by the collapsed cone convolution (CCC) and Monte Carlo (MCMonaco ) algorithms, built into the commercially available Monaco version 5.11 TPS, are compared with measurements carried out on an Elekta Axesse linear accelerator. For the measurements, ion chambers, thermoluminescent dosimeters, and EBT3 film are used. The BEAMnrc code, built on the EGSnrc system, is used to create a model of the Elekta Axesse with the Agility collimation system, and the space phase file generated is scored by DOSXYZnrc to generate the dose distributions (MCEGSnrc ). Three different irradiation scenarios are considered: (a) a 10 × 10 cm2 field, (b) an IMRT prostate plan, and (c) a three-field lung plan. Monaco's calculations, experimental measurements, and Monte Carlo simulations are carried out in water and/or in an ICRP110 phantom. RESULTS: For the 10 × 10 cm2 field case, CCC underestimated the dose, compared to ion chamber measurements, by 13% (differences relative to the algorithm) on average between the 5% and the ≈2% isodoses. MCMonaco underestimated the dose only from approximately the 2% isodose for this case. Qualitatively similar results were observed for the studied IMRT case when compared to film dosimetry. For the three-field lung plan, dose underestimations of up to ≈90% for MCMonaco and ≈60% for CCC, relative to MCEGSnrc simulations, were observed in mean dose to organs located beyond the 2% isodose. CONCLUSIONS: This work shows that Monaco underestimates out-of-field doses in almost all the cases considered. Thus, it does not describe dose distribution beyond the border of the field accurately. This is in agreement with previously published works reporting similar results for other TPSs. Analytical models for out-of-field dose assessment, MC simulations or experimental measurements may be an adequate alternative for this purpose.
Asunto(s)
Aceleradores de Partículas , Planificación de la Radioterapia Asistida por Computador , Algoritmos , Método de Montecarlo , Fantasmas de Imagen , Radiometría , Dosificación RadioterapéuticaRESUMEN
Anticancer regimens for Hodgkin lymphoma (HL) patients include highly genotoxic drugs that have been very successful in killing tumor cells and providing a 90% disease-free survival at five years. However, some of these treatments do not have a specific cell target, damaging both cancerous and normal cells. Thus, HL survivors have a high risk of developing new primary cancers, both hematologic and solid tumors, which have been related to treatment. Several studies have shown that after treatment, HL patients and survivors present persistent chromosomal instability, including nonclonal chromosomal aberrations. The frequency and type of chromosomal abnormalities appear to depend on the type of therapy and the cell type examined. For example, MOPP chemotherapy affects hematopoietic and germ stem cells leading to long-term genotoxic effects and azoospermia, while ABVD chemotherapy affects transiently sperm cells, with most of the patients showing recovery of spermatogenesis. Both regimens have long-term effects in somatic cells, presenting nonclonal chromosomal aberrations and genomic chaos in a fraction of noncancerous cells. This is a source of karyotypic heterogeneity that could eventually generate a more stable population acquiring clonal chromosomal aberrations and leading towards the development of a new cancer.
Asunto(s)
Aberraciones Cromosómicas , Daño del ADN , Inestabilidad Genómica , Enfermedad de Hodgkin/genética , Antineoplásicos/toxicidad , Células Germinativas/metabolismo , HumanosRESUMEN
Background: A second primary cancer is that occurring in patients who have survived a previous cancer and its frequency is 16 percent. Aim: To identify and characterize patients with a second primary cancer treated in a clinical hospital. Material and methods: Review of the database of the Clinical Oncology Unit of a surgical department between 2004 and 2012. Among 4,007 patients operated for cancer, 196 (mean age 63 years, 51 percent women) had a previous history of cancer, whose medical records were reviewed. Results: In the study period the frequency of a second primary cancer in endocrinological, thoracic and digestive surgery was 4.9 percent. There was a mean lapse of 8.2 years between the first and second cancer and 24 percent of patients had a family history of cancer. The second primary lesions were located in colon in 26 percent, stomach in 19 percent, thyroid in 16 percent, rectum in 12 percent, pancreas in 8 percent and lung in 8 percent. Sixty five percent of lesions was diagnosed in stage IV with peritoneal and lung metastases in 38 and 25 percent respectively. Conclusions: Second primary cancer is uncommon in this series. The high frequency of colon cancer must be highlighted. Due to the lapse between the first and second tumor, follow up of patients treated for cancer should be maintained for at least eight years.
Introducción: El segundo cáncer primario (SCP) es aquel ocurrido en pacientes sobrevivientes de cáncer y tiene una frecuencia de 16 por ciento según Surveillance Epidemiology and End Results. Objetivo: Identificar y caracterizar a los pacientes con SCP en nuestro hospital entre los años 2004 y 2012. Materiales y métodos: Estudio observacional descriptivo retrospectivo. Revisión en base de datos registrados en la Unidad de Oncología Clínica del Departamento de Cirugía entre 2004-2012. De un total de 4.007 pacientes operados por cáncer, se identificaron 196 con antecedentes previos de cáncer. Revisión de fichas Clínicas, Registro en programa Excel y análisis en sistema Stata v11. Resultados: El SCP en cirugía endocrinológica, torácica, coloproctológica y digestiva tiene una frecuencia de 4,9 por ciento en el período estudiado. La edad promedio de presentación es 63 años, 51 por ciento mujeres y 48 por ciento varones. Intervalo promedio de 8,2 años entre el primer y el segundo cáncer. 23,47 por ciento tenía antecedentes familiares. Los pacientes presentaron cáncer de colon en un 26,02 por ciento, seguido de cáncer gástrico 18,88 por ciento, cáncer de tiroides 15,8 por ciento, cáncer de recto 11,73 por ciento, cáncer de páncreas 8,16 por ciento, cáncer de pulmón 7,65 por ciento. El 65,5 por ciento fue diagnosticado en etapa IV, siendo las metástasis más frecuentes al peritoneo (37,5 por ciento) y pulmón (25 por ciento). Conclusión: El segundo primario es una entidad poco frecuente en nuestro medio, destacando la alta incidencia de cáncer de colon. El intervalo de presentación sugiere mantener un seguimiento prolongado de al menos 8 años.